Perioperative efficacy of triple anti-platelet therapy in patients undergoing coronary stent implantation / 中国医师进修杂志

ABSTRACT

Objective To evaluate the efficacy and safety of low-dose tirofiban combined with dual anti-platelet therapy in patients undergoing coronary stent implantation for acute coronary syndrome.Methods From October 2010 to July 2013,a total of 306 patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome were enrolled and divided into 2 groupstriple anti-platelet group (156 patients) and dual anti-platelet group (150 patients).Patients in triple anti-platelet group received low-dose tirofiban with starting dose 0.4 μ g/(kg· min) and 0.1 μ g/(kg·min) after 30 min for 24-36 h on the basis of dual anti-platelet therapy.Patients in dual anti-platelet group only received dual anti-platelet therapy.Information of the bleeding time,the clotting time,the platelet count change,the major adverse cardiac events (MACE),bleeding events in both groups were observed and the efficacy and safety were evaluated.Results The rate of thrombus of stent and target vessel revascularization were 2.0％ (3/150) and 2.7％ (4/150) in dual anti-platelet group,0.6％ (1/156) and 0.6％ (1/156) in triple anti-platelet group,and there were no significant differences between two groups (P ＞ 0.05).There was no significant difference in the rate of bleeding events between two groups (P ＞ 0.05).The bleeding time and clotting time in two groups were extended at different degree,but there were no significant differences (P ＞ 0.05).Conclusions Additional use of low-dose tirofiban is effective and safe in patients undergoing coronary stent implantation for acute coronary syndrome.It could not only reduce the MACE rate but also improve the coronary blood flow.Moreover,it does not increase the bleeding events.